Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Greenwich LifeSciences, Inc. GLSI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$50.00
+92.2%

Greenwich LifeSciences, Inc. (GLSI) is a Biotechnology company in the Healthcare sector, currently trading at $26.02. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is GLSI = $50 (+92.2% upside).

Valuation: GLSI trades at a trailing Price-to-Earnings (P/E) of -17.7 (S&P 500 average ~25).

Net income is $16M (loss), growing at -54%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $3M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.62 (strong liquidity). Debt-to-assets is 0%. Total assets: $4M.

Analyst outlook: 2 / 2 analysts rate GLSI as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 69/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$50.00
▲ 92.16% Upside
Average Price Target
The 12-month price target for Greenwich LifeSciences, Inc. is $50.00.

GLSI SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 69/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GLSI

✓
VALUE Pass
69/100
GLSI trades at a trailing Price-to-Earnings (P/E) of -17.7 (S&P 500 average ~25). Forward PEG -1.9 — Peter Lynch undervalued (≤1.0). Trailing PEG 2.4. Analyst consensus target is $50, implying +92.2% from the current price $26. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GLSI: +0%/yr revenue is, -54%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet GLSI: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.62 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
GLSI: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate GLSI as buy (100%). Analyst consensus target is $50 (+92.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7.78-34.1
Volume115.59K
Avg Volume (30D)325.94K
Market Cap$360.5M
Beta (1Y)1.53
Share Statistics
EPS (TTM)-1.21
Shares Outstanding$13.01M
IPO Date2020-09-25
Employees4
CEOSnehal S. Patel
Financial Highlights & Ratios
EBITDA$-15.79M
Net Income$-15.79M
Operating Income$-16.01M
Total Cash$4.09M
Net Debt$-4.09M
Total Assets$4.09M
Price / Earnings (P/E)-21.5
Analyst Forecast
1Y Price Target$50.00
Target High$50.00
Target Low$50.00
Upside+92.2%
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS3968791083

Price Chart

Track all markets on TradingView
GLSI
Greenwich LifeSciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
7.78 52WK RANGE 34.10

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 AVXL
AVXL
Anavex Life Sciences Corp.
$3.12
+0.32%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.68
+6.77%
 MNOV
MNOV
MediciNova, Inc.
$1.41
-2.08%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message